Overview of Avon

Property	Description
Active ingredient	Ginkgo Biloba Extract
Form	Oral Tablet or Capsule
Pharmacological class	Phytomedicine, Vasoactive Agent
Common use	Supports Cognitive enhancer function
Origin	Natural (Derived from Ginkgo Biloba leaves)

What Type of Medicine Is Avon? (Identity and Class)

Avon is classified as an oral Phytomedicine, which is a medicinal product of a Natural origin derived from the dried green leaves of the Ginkgo Biloba tree. It is supplied as an oral Tablet or capsule intended for systemic support, often targeting the adult patient group seeking daily support for general brain function. Ginkgo folium is recognized in the context of anti-dementia drugs, which underscores its historical and clinical relevance. Functionally, the preparation is considered a Vasoactive Agent due to its influence on blood vessel dynamics, and a Nootropic for its supportive role in mental function. This foundational identity establishes Avon as a botanical therapy focusing on systemic circulation and neurological support.

Composition: Active Ingredients and Standardized Extract

The efficacy of Avon is linked to its specific chemical profile, featuring two primary classes of active ingredients: Ginkgo Flavone Glycosides and Terpene Lactones. The Ginkgo Flavone Glycosides are recognized for their strong Antioxidant properties, while the Terpene Lactones, including Ginkgolides and Bilobalide, are distinctive to this plant and contribute to the product's unique pharmacological action. These components serve as the main active constituents in supporting healthy blood flow and cognitive vitality. Avon is produced as a Standardized Extract, a manufacturing feature that guarantees a consistent concentration of the key compounds in every oral dose, typically targeting 22% to 27% Ginkgo Flavone Glycosides and 5% to 7% Terpene Lactones.

General Purpose and Supporting Function

The overall purpose of Avon is to serve as a general Cognitive enhancer by supporting the physiological systems essential for optimal brain performance. The extract's action is based on principles such as Vascular Regulation, which assists in supporting efficient blood flow (circulation), and its strong Antioxidant capacity, which helps protect tissues from damage resulting from oxidative stress. This dual-action profile makes Avon suitable for individuals seeking support for general memory and concentration. By consistently supporting these two fundamental mechanisms, the preparation is positioned to maintain the overall functional capacity of the circulatory and cognitive systems.

Regulatory References

Ginkgo Biloba - StatPearls - NCBI Bookshelf

What side effects are possible with Avon?

Possible Side Effects and Safety Information

The safety profile of standardized Ginkgo Biloba extract, the active ingredient in Avon, is defined by regulatory documents that classify potential adverse reactions by frequency and physiological system.

Officially documented side effects are most often categorized as Rare or Very Rare, with some reported as Common in the context of certain uses.

Common Reactions may include Headache.
Rare Reactions may involve Gastrointestinal system disorders (e.g., nausea, vomiting, diarrhoea, abdominal pain) and Nervous system disorders (e.g., dizziness), as well as Allergic skin reactions (e.g., pruritus, rash).

Serious Adverse Reactions and Constraints

Specific regulatory notes highlight the potential for Bleeding events (such as in the eye, brain, or gut), which are reported in sporadic case reports. This concern is the basis for a mandatory safety restriction: the medicine must be discontinued at least two weeks prior to any scheduled surgical or medical procedure.

Use is contraindicated (should not be used) in individuals with a known tendency to bleed (haemorrhagic diathesis) or known hypersensitivity to Ginkgo Biloba extract.

Population-Specific Safety

The product is contraindicated for use during Pregnancy due to the potential for increased bleeding risk and is generally not recommended for children and adolescents due to a lack of sufficient data. A specific warning addresses patients with Epilepsy, noting that the onset of further seizures cannot be ruled out with its use.

Overdose and Emergency Response

An overdose of Avon (Interferon beta-1a) is rare due to its prescribed injection dosage, but it is a serious medical emergency. This medication is a biologic agent used for relapsing forms of Multiple Sclerosis (MS). Because it is not a traditional tablet and is administered on a weekly schedule, any suspected overdose should be immediately reported to emergency services or a Poison Control Center.

Signs of Potential Overdose

While the specific signs of an Avon overdose are not fully characterized, excessive administration may lead to a worsening of known serious side effects, which include, but are not limited to:

System	Possible Manifestation
Cardiovascular	Worsening symptoms of heart failure
Hematologic	Severe blood cell abnormalities
Hepatic	Signs of acute liver injury (e.g., yellowing of the skin/eyes, dark urine)
Neurologic	Severe confusion, seizures, or loss of consciousness

When to Seek Help

Call 911 (or your local emergency number) immediately if you or someone else has received a dose significantly larger than prescribed or shows any of the severe symptoms listed above. Do not wait for symptoms to worsen. Provide the healthcare professionals with the exact name of the medication (Interferon beta-1a) and the approximate amount administered.

Therapeutic Uses of Avon

Avon is commonly used to help with age-related cognitive impairment. It may be applied across therapeutic domains where additional symptomatic support is needed. The preparation is relevant for managing symptoms that interfere with daily comfort, such as difficulties in memory, focus, and attention associated with mild dementia. It is also relevant for easing symptomatic peripheral circulatory issues, including leg pain associated with walking (Intermittent Claudication), and dizziness or unsteadiness (vertigo).

The extract is commonly used to help with symptomatic management for adults with mild cognitive issues. The support offered contributes to easing the overall symptom load, particularly for symptoms that interfere with daily functioning. The medicine is relevant in contexts marked by increased discomfort or tension, and it may assist with maintaining functional stability.

Quick Fact: Supportive Relief for Walking Discomfort

The medication is relevant for managing symptoms that interfere with daily comfort. It specifically plays a role in managing the pain and cramping in the legs that can occur during physical activity due to circulation issues.

Regulatory References

European Medicines Agency (EMA) assessment of Ginkgo leaf

Eligibility and Restrictions for Use

Eligibility Profile: Who Can and Cannot Use Avon?

Official regulatory documents define the population eligible to use Avon (Ginkgo Biloba Extract) and establish clear rules for exclusion and restricted use. The medicine is intended for use by adults and older people. Use in children and adolescents under 18 years of age is not recommended because official data regarding its safety and efficacy in these groups are insufficient, meaning use is not established.

Absolute Contraindications

Avon is formally contraindicated and must not be used in the following populations:

Individuals who are pregnant.
Patients with known hypersensitivity (allergy) to Ginkgo preparations or any excipient in the product.

Conditional Use and Restrictions

Use is permitted only with caution in patients with specific pre-existing conditions. Those with epilepsy should be cautious due to the risk of further seizure onset. Patients with a bleeding disorder must use the medicine with care. Regulatory guidance advises that Avon must be discontinued at least 2 weeks prior to any scheduled surgery to mitigate the risk of bleeding. Use is also not recommended for women of childbearing potential not using contraception or during lactation. This official profile restricts the medicine to healthy adults and strictly governs use where certain health or physiological statuses are present.

What should I know about interactions with other medicines?

Avon (Ginkgo Biloba extract) has officially documented interaction patterns primarily involving two mechanisms: pharmacodynamic reinforcement and pharmacokinetic modulation.

The pharmacodynamic interaction involves an additive effect on blood clotting, which carries an increased risk of bruising and bleeding when co-administered with anticoagulant agents (such as Warfarin) and anti-platelet agents (such as Aspirin and NSAIDs). Due to this documented risk, regulatory labeling specifies that administration of Avon must be discontinued at least two weeks prior to any scheduled surgical procedure.

The pharmacokinetic interaction involves the modulation of drug-metabolizing enzymes, including the induction and weak inhibition of CYP3A4 and the induction of CYP2C9 and CYP2C19. These effects may be clinically significant for co-administered drugs with a narrow therapeutic index. This modulation forms the basis of the restriction that co-administration with the antiretroviral agent Efavirenz is not recommended, as it may lead to decreased plasma concentrations of Efavirenz. Other exposure changes include the potential for raised plasma levels of Nifedipine. A population-specific caution also exists for patients with epilepsy, as a potential for increased seizure risk cannot be excluded.

Mechanism of Action

Avon (Interferon beta-1a) is a recombinant protein classified as an immunomodulator, exhibiting pleiotropic effects within the central nervous system and the periphery. The compound functions as an agonist for the ubiquitous Type I interferon receptor (IFNAR1/IFNAR2) heterodimer located on target cell surfaces, including immune cells and glia. Upon binding, the receptor-associated Janus Kinases (JAKs), specifically JAK1 and Tyk2, undergo rapid trans-autophosphorylation. This phosphorylation event recruits and activates Signal Transducers and Activators of Transcription (STAT) proteins, primarily STAT1 and STAT2.

Activated STATs dimerize, translocate to the cell nucleus, and bind to Interferon-Stimulated Response Elements (ISRE) in the promoter region of Interferon-Stimulated Genes (ISGs). The resulting upregulation of ISGs mediates multiple intracellular consequences, including the inhibition of T-cell proliferation and the modulation of inflammatory cytokine and chemokine expression by various cellular populations. System-level physiological modulation involves a shift in the inflammatory and migratory profile of peripheral immune cells, leading to a modified cellular trafficking pattern across the blood-brain barrier.

Dosage and Administration Information

How to Use Avon

This section outlines the standardized administration protocol for Avon (Standardized Ginkgo Biloba Extract). This information focuses solely on the manner of use and does not address safety, mechanism, or therapeutic effects.

Official Administration Guidelines

Instruction	Detail
Route of Administration	Oral (by mouth) via film-coated tablets, capsules, or an oral solution.
Standard Daily Dosing	Typically 120 mg to 240 mg of the standardized extract per day for adult use.
Frequency and Timing	The medicine should be administered with or after food. The total dose is often divided into two or three administrations, though the 240 mg strength is frequently taken as a single daily dose.
Preparation Constraints	Tablets and capsules must be swallowed whole. Oral solution formulations require accurate measurement and dilution with water prior to ingestion.
Age-Group Rules	The standard adult dose applies to the elderly. Use is not recommended in individuals under 18 years of age.

Course Duration and Use Protocol

The usage protocol is structured around defined periods of administration before clinical review. For age-related cognitive issues, the protocol typically specifies a treatment duration of three months before a medical reassessment is required to evaluate the continued need for the product. For minor circulatory issues, a shorter period of approximately two weeks of use is often indicated before review.

This structure ensures the medicine is taken consistently at the correct frequency and in the specified amount, adhering to the standardized protocol for administration.

Recent Clinical Evidence

Research evidence / Overview of Studies for Avon

Evidence Supporting Cognitive Function and Memory Support

Research has primarily examined Avon in the context of research exploring cognitive function in older adults facing age-related memory issues and the symptoms of mild-to-moderate dementia. Studies conducted for this purpose include short-term Randomized Controlled Trials (RCTs), as well as large-scale, long-term studies that explored the preparation was studied for the prevention of decline. Some short-term trials described patterns observed in the studies related to measured change in cognitive function scores among subjects with established mild-to-moderate dementia. However, findings related to changes in functional capacity may be variable or mixed across different study groups.

Long-term effects are not fully established regarding the sustained symptomatic response beyond one year. Research explored the extract's use in preventing cognitive decline in healthy individuals, and subgroup findings are uncertain. Research is ongoing to better understand the long-term patterns.

Research on Symptomatic Relief of Leg Pain During Walking

Avon was studied for its use in research exploring discomfort and pain in the legs that may occur during physical activity due to circulation issues (intermittent claudication). The research primarily examined the extract through short-term RCTs, focusing on patient-reported outcomes describing perceived discomfort, specifically measuring the Absolute Claudication Distance. Many individual trials described patterns observed in the studies related to measurements of walking distance compared to baseline. However, comprehensive scientific reviews indicate that the magnitude of the measured change was often small and evidence quality varies across studies regarding the consistency of results.

Evidence is limited regarding the long-term impact on the underlying circulatory condition. Follow-up durations were limited, generally only focusing on changes observed over six months or less.

Studies Investigating Chronic Dizziness and Balance Issues

Avon was evaluated in research examining conditions characterized by fluctuating or episodic manifestations such as chronic vertigo and dizziness. Studies include short-term RCTs that research examined primarily patient-reported outcomes describing perceived discomfort. Some short-term trials described patterns observed in the studies related to measured improvement in subjective impairment scores, such as the reported intensity and frequency of dizziness. The research has focused mainly on chronic, non-specific symptoms and may often exclude patients with specific, clearly defined inner-ear disorders.

Evidence Gaps and Areas of Scientific Uncertainty

Evidence quality varies across studies, particularly between older and newer trials, leading to findings were mixed for some indications. Sample sizes were modest in some of the trials, meaning the results apply only to the populations studied. Data for certain groups remain insufficient, particularly for long-term use and for patients with multiple health issues. Overall, the evidence contributes to the broader evidence landscape but evidence highlights what is known — and what is still uncertain.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Avon (FAQ)

Q: How quickly can I expect to see the benefits of Avon?

A: Regulatory documents indicate that assessment of effectiveness may not be immediate. For issues related to age-related cognitive function, three months of consistent use is typically the duration after which reassessment is considered for continued use of the product. For minor circulatory issues, a shorter period of approximately two weeks is often indicated before review.

Q: Does Avon start working immediately to prevent relapses or symptoms?

A: Official guidance establishes a minimum period of use before symptomatic improvement is assessed. This suggests that effects may not be apparent right away. For example, a three-month period is specified for reviewing cognitive issues, which is when the medicine’s effect is expected to be clearer.

Q: How long is Avon typically prescribed for the treatment of MS or other conditions?

A: For age-related cognitive issues, regulatory documentation specifies a typical treatment duration of three months before a medical reassessment. For minor circulatory issues, approximately two weeks of use is often indicated before review. The total length of use, or whether use is continued, is generally determined by a healthcare provider after this initial assessment period.

Q: Is it normal to feel flu-like symptoms after an Avon injection or starting the tablet?

A: The official product information for the oral form of Avon does not explicitly list flu-like symptoms as an adverse reaction. Reported effects may include headache, dizziness, and rare gastrointestinal disturbances like nausea or diarrhea.

Q: Can Avon cause changes in mood or lead to depression?

A: Official product information does not explicitly list changes in mood or depression as potential side effects. The reported adverse reactions for the nervous system mainly include headache and dizziness.

Q: Is there a cumulative effect of Avon over several years of use?

A: Research reviewed by regulatory bodies indicates that the long-term patterns of use beyond one year are not fully established. Therefore, there is limited data on the sustained symptomatic response over several years.

Q: What are the potential effects of Avon on vision or eye health?

A: Regulatory safety information highlights the potential for bleeding events. Sporadic case reports have noted bleeding in various organs, including the eye (ocular hemorrhage).

Q: What happens if I miss my scheduled Avon dose?

A: Official product information states that if a dose is missed, the user should continue with the next scheduled dose at the usual time. It is stated that a double dose should not be taken to make up for the missed one.

Q: Where does Avon get injected, and is it a subcutaneous or intramuscular injection?

A: The standardized extract of Avon is an oral preparation, supplied as a tablet or capsule, and is taken by mouth. It is not administered via injection, and instructions for injection sites do not apply to this product.

Q: Why is Avon given only once a week for MS treatment?

A: The standardized extract of Avon is officially approved as an oral product intended for daily use. Official regulatory guidance specifies that the total daily dose is often divided into two or three administrations, or a single daily dose for the highest strength. This product is not authorized as a once-weekly injection.

Q: Is it normal for the injection site to be sore or red after using Avon?

A: The official product for Avon is the oral (by mouth) preparation in tablet or capsule form. Therefore, there are no instructions or warnings regarding injection site reactions for this product.

Q: Is it possible for Avon to stop working over time?

A: Regulatory guidance specifies that if there is no symptomatic improvement after a defined period (e.g., three months), the continued need for the medicine is subject to periodic evaluation by a healthcare professional.

Q: Does Avon require special storage conditions, like refrigeration?

A: Official product labeling requires that Avon be stored according to the specific temperature range stated on the packaging. Official requirements specify that the product should also be protected from both light and moisture to help maintain its quality.

Q: Why is the starting dose of Avon often lower than the maintenance dose?

A: Official regulatory guidance for this product lists a standard daily dosing range for adult use. It does not include a specific dose titration or starting dose protocol that is typically lower than the maintenance dose.

Q: Are there any long-term research studies on the safety of Avon?

A: Official documents indicate that safety data for certain areas, such as reproductive toxicity, are insufficient. The extent of long-term safety data is therefore considered limited, and the full establishment of long-term safety is restricted.

Q: What is the difference in side effects between Avon tablet and injection?

A: The official regulatory approval for Avon is for the oral tablet or capsule form. As this product is not an injection, there is no official regulatory data comparing the side effects of a tablet versus an injection.

Q: Does Avon affect how long other medications stay in my system?

A: Official information states that Avon modulates (affects the activity of) certain drug-metabolizing enzymes, including CYP3A4, CYP2C9, and CYP2C19. This interaction may potentially change the concentration or elimination rate of other medications, especially those where small changes in dose can have significant effects.

Q: Are there any known interactions between Avon and alcohol?

A: Regulatory documents do not explicitly list an interaction with ethanol (drinking alcohol). However, some liquid formulations of the product may contain alcohol, and this is a factor to consider, particularly when taking other medications that may interact with alcohol or affect the central nervous system.

Q: Can Avon impact my ability to drive or operate machinery?

A: Official product information notes that side effects such as dizziness and headache are possible. Regulatory documents indicate that if these adverse effects occur, caution regarding driving or operating machinery may be necessary.

Q: What should I do if my injection pen or syringe seems to be malfunctioning?

A: The official product for Avon is an oral tablet or capsule and is not provided in a pre-filled syringe or injection pen. Therefore, instructions for managing a malfunctioning injection device do not apply.

How should Avon be stored and disposed of?

How to Store and Dispose of Avon?

Storage/Disposal Domain	Official Requirements & Practical Implications
Temperature & Environmental Protection	The product must be stored and held under conditions to maintain its original quality, strength, and purity, strictly adhering to the specific temperature range stated on the regulatory labeling (e.g., 2 C to 8 C or room temperature). Storage must also protect the medicine from light and moisture as specified in the official packaging requirements.
In-Use Stability and Handling	If the product requires preparation, dilution, or mixing, the official label defines the stability period (e.g., discard after X hours or days) for the prepared medicine. The container and closure system must maintain integrity to prevent contamination or deterioration. Products exposed to improper storage conditions are officially prohibited from being salvaged.
Disposal Instructions	Disposal must follow any explicit instructions on the official labeling, particularly for certain high-risk drugs that may be directed for immediate flushing to prevent accidental ingestion. For medicines lacking specific instructions, disposal should be done by mixing the drug with an undesirable substance (e.g., dirt, used coffee grounds) and sealing it in a container before placing it in household trash, or by using a drug take-back program.

Avon